Tag: Pharmazz

Pharmazz Inc. Announces Positive Results of Phase III Clinical Trial Evaluating Sovateltide as a Treatment for Acute Cerebral Ischemic Stroke

Sovateltide produced a statistically significant and clinically meaningful improvement in neurological outcomes in acute cerebral ischemic stroke patients 90 days post-treatment Sovateltide demonstrated a highly favorable ordinal shift in the modified Rankin Scale (mRS) score and a significantly (p=0.0045) greater number of […]

Pharmazz Inc. Announces Completion of Enrollment of Phase III Clinical Trial Evaluating Sovateltide as a Treatment for Acute Cerebral Ischemic Stroke

Sovateltide is an endothelin B receptor agonist that increases blood flow, shows anti-apoptotic activity, protects neural mitochondria, and produces neurovascular remodeling WILLOWBROOK, Ill., Feb. 17, 2022 (GLOBE NEWSWIRE) — Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing […]